Literature DB >> 31087573

Wulingsan (Oryeongsan/Goreisan) ameliorate lipid metabolism of obesity rats via regulation of the plasma metabolic profiling.

Xin-Ru Xue1, Jin-Jue Xue2, Xiang Cui1, Deng-Yue Zhang1, Chao-Ying Lu1, Yu-Meng Shen1, Shu Jiang1.   

Abstract

OBJECTIVES: Wulingsan has been used to cure disease about disorders related to fluid balance for thousands of years. The clinical practice of modern Chinese medicine has found that Wulingsan has the effect on reducing weight and fat, but its mechanism is not clear. This study investigated its effects on obesity rats and explored the underlying mechanisms by analyzing the plasma metabolic profiling.
METHODS: The effects of Wulingsan on obesity were evaluated with obesity rats induced by high-fat diet. Ultra high performance liquid chromatography coupled with quadrupole time of flight mass spectrometry (UPLC-Q-TOF/MS) was performed to discover potential biomarkers and evaluate whether Wulingsan could regulate these biomarkers. The levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) in serum were assessed by ELISA kits.
RESULTS: Remarkably, TG, TC, HDL-C and LDL-C in obesity rats were ameliorated after oral administration of Wulingsan. Further investigation indicated that the plasma metabolic profiles were clearly improved. Twelve potential biomarkers were identified. After intervention, these biomarkers turned back to normal level at some extent.
CONCLUSION: The results showed that Wulingsan extract groups were normalized. Additionally, this study also showed that the metabonomics method was a promising tool to unravel how traditional Chinese medicines worked and these data can provide scientific basis for clinical application of Wulingsan.
© 2019 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Wulingsan (Oryeongsan/Goreisan); obesity; plasma metabolic profiling

Mesh:

Substances:

Year:  2019        PMID: 31087573     DOI: 10.1002/bab.1766

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  1 in total

1.  The efficacy and safety of Wulingsan modified formulas for chronic heart failure patients: a systematic review and meta-analysis.

Authors:  Ziyun Li; Lang Ren; Renjun Gu; Conghui Zhou; Xu Tong; Jingqing Hu
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.